Philippe Moreau

TL;DR: Evaluated progression-free survival (PFS), duration of response (DOR) by depth of response and time to best response using data from the double-blind phase 3 TOURMALINE-MM1 trial of ixazomiblenalidomide-dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory MM.

TL;DR: In this paper , a theoretically-based clinical framework is proposed to support breast cancer survivors at each stage of the return-to-work process, which considers several essential aspects of supportive care, such as: (i) helping the patient actively self-manage, by considering her to be the main decision-maker; (ii) respecting and adapting to the patient's choice of professional project; (iii) respecting the temporality of patient's choices; (iv) proposing tailored interventions; (v) implementing simple tools to promote the return to work, shared representation between the patient and a multidisciplinary team, and improvement of working conditions and the knowledge of health and occupational professionals, and maintaining certain flexibility aimed at proposing, but never imposing, changes in practices.

TL;DR: The goal of this review is to examine the feasibility of functional imaging, especially FDG-PET/CT, for therapeutic assessment and MRD detection in MM.

TL;DR: Health-related quality of life results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.

TL;DR: Results show that POM’+ LoDEX should be a standard treatment after lenalidomide and bortezomib, including in SD patients, and significantly extends OS in RRMM vs. high-dose dexamethasone.